Valneva (VALN) has released an update.
Valneva SE has achieved a significant milestone with Health Canada’s approval of IXCHIQ®, the world’s first chikungunya vaccine, following prior FDA approval and anticipated EMA authorization. The vaccine addresses a growing need as millions travel to chikungunya-endemic regions, with Valneva aiming to commence Canadian sales by late 2024. The company’s commitment, supported by CEPI and collaborations, extends towards making the vaccine accessible globally, particularly in low- and middle-income countries.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
